Genentech, a subsidiary of Roche, is making significant strides in the field of antibody-drug conjugates (ADCs) by partnering with DualityBio. This collaboration involves an upfront payment of $45 million and has the potential to exceed $1 billion through various milestone achievements. With a focus on addressing the needs of patients whose cancers become resistant to existing ADC therapies, Genentech is positioning itself at the forefront of innovation in oncology.
Addressing Unmet Needs in Cancer Treatment
As ADCs like AstraZeneca and Daiichi Sankyo’s Enhertu and Gilead’s Trodelvy gain approval for first-line treatments, a critical gap has emerged. Patients progressing after these therapies often show reduced responsiveness to the topoisomerase inhibitors delivered by these ADCs. Recognizing this unmet need, Genentech has turned to DualityBio, a biotech firm with promising solutions aimed at these hard-to-treat cases.
Leveraging DualityBio’s Dupac Platform
The collaboration enables Genentech to utilize DualityBio’s Dupac platform, which is specifically designed to maintain efficacy in tumors that have progressed on current topoisomerase-based ADCs. Through this partnership, Genentech will guide the development of ADCs that incorporate Dupac payloads targeting specific cancer markers. DualityBio will take charge of advancing these candidates through initial clinical stages, capitalizing on China’s advantages in early-stage drug development.
Progress and Promising Data
In the past 16 months, DualityBio has made strides in the research and presentation of its Dupac payloads. Notably, last year, the company shared two abstracts detailing the potential of its mRNA translation inhibitor, DUP5, which aims to enhance the effectiveness of GSK’s BCMA-directed ADC, Blenrep. This data demonstrates DualityBio’s commitment to advancing ADC technology and its potential to significantly impact patient outcomes.
Innovative Payloads for Targeted Therapies
In addition to DUP5, DualityBio has showcased a derivative of ecteinascidin that could outperform existing TA-MUC1-targeting ADCs, like Daiichi’s DS-3939a. The research indicated that the DUP9 payload effectively targets and kills cells expressing EGFR and DLL3, further illustrating the versatility and effectiveness of DualityBio’s payloads. Plans are already in place to initiate human trials for the TA-MUC1 ADC next year.
Expanding DualityBio’s Collaborative Reach
The burgeoning interest in DualityBio’s technology is evident in its partnerships with several prominent Western drugmakers. In recent years, companies such as BioNTech, GSK, and BeiGene (now BeOne Medicines) have all secured deals for DualityBio’s ADC candidates. While these agreements have primarily focused on the topoisomerase platform, DualityBio is diversifying its portfolio by exploring collaborations based on its bispecific platform, as demonstrated by a recent agreement with Avenzo Therapeutics.
A Holistic Approach to ADC Development
Genentech’s collaboration with DualityBio marks a critical step not only in enhancing ADC technology but also in addressing broader challenges in cancer treatment. By combining DualityBio’s innovative payloads with Genentech’s extensive expertise, this partnership aims to create targeted therapies that can effectively treat patients who have limited options due to previous treatments.
Conclusion: A Vision for the Future of Oncology
Through its strategic investment in DualityBio, Genentech is poised to make significant contributions to the field of cancer therapy, particularly for ADC-resistant cancers. This partnership not only highlights the importance of innovation in biotechnology but also underscores the need for continuous development of effective treatments that can adapt to the evolving landscape of cancer resistance. As the collaboration unfolds, it may pave the way for breakthroughs that could redefine patient care in oncology.
- Key Takeaways:
- Genentech invests $45 million upfront in DualityBio, with potential for over $1 billion in milestones.
- The partnership focuses on developing ADCs that address resistance in cancer treatments.
- DualityBio’s Dupac platform promises to enhance efficacy in tumors that have progressed on existing therapies.
- Ongoing research showcases innovative payloads that could outperform current ADC options.
- Collaborative efforts expand DualityBio’s influence in the biotech industry, attracting attention from major drugmakers.
Read more → www.fiercebiotech.com